ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 4 of 4 for:    verrica

Cantharidin Application in Molluscum Patients-1 (CAMP-1)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03377790
Recruitment Status : Active, not recruiting
First Posted : December 19, 2017
Last Update Posted : September 14, 2018
Sponsor:
Collaborators:
Instat Consulting, Inc.
Paidion Research, Inc.
Database Integrations, Inc.
Information provided by (Responsible Party):
Verrica Pharmaceuticals Inc.

Brief Summary:
This study is a Phase 3, randomized, double-blind, placebo-controlled, pivotal study to evaluate the safety and efficacy of VP-102 topical film-forming solution in subjects with Molluscum Contagiosum. VP-102 will be applied once every 21 days for up to 4 applications, to treatable molluscum contagiosum (molluscum) lesions on subjects 2 years and older. Efficacy will be assessed as the proportion of subjects achieving complete clearance of all treatable molluscum lesions (baseline and new) on the Day 84 visit.

Condition or disease Intervention/treatment Phase
Molluscum Contagiosum Drug: VP-102 Drug: Placebo Device: Applicator Phase 3

Detailed Description:

This is a Phase 3, multi-center, randomized, double-blind, placebo (vehicle)-controlled, pivotal study that will be conducted in the United States to determine the efficacy and safety of VP-102 following treatment of molluscum lesions for up to 4 treatments, every 21 days, with VP-102/placebo in 250 subjects. Subjects will receive active VP-102 or placebo in a 3:2 ratio. Study drug (VP-102 or placebo) will be supplied in single-use applicators.

The film-forming Study drug solution will be applied and left on the lesions for 24 hours before the subject and/or parents/guardian washes the lesions. Study drug may be removed prior to the 24-hour time point in the event treatment-emergent AEs are experienced.

Molluscum lesions will be treated without occlusion in all anatomic areas including the face, trunk, back, arms, legs, hands, feet, anogenital region and buttocks.


Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 266 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Pivotal Study to Evaluate the Safety and Efficacy of VP-102 Topical Film-Forming Solution [0.7% (w/v) Cantharidin] in Subjects (2 Years and Older) With Molluscum Contagiosum
Actual Study Start Date : March 21, 2018
Estimated Primary Completion Date : November 19, 2018
Estimated Study Completion Date : November 19, 2018

Arm Intervention/treatment
Active Comparator: VP-102
VP-102 Film Forming Solution applied via a prefilled applicator to affected area every 21 days
Drug: VP-102
VP-102 Active will be administered via the applicator to Molluscum lesions
Other Name: Topical Film Forming Solution

Device: Applicator
Used to apply the topical film forming Active or Placebo to Molluscum.
Other Name: For use in applying VP-102 Drug or Placebo Vehicle

Placebo Comparator: Placebo
Vehicle Film Forming Solution applied via a prefilled applicator to affected area every 21 days
Drug: Placebo
Placebo to be applied via the applicator to Molluscum lesions
Other Name: Vehicle Control Topical Film Forming Solution without VP-102

Device: Applicator
Used to apply the topical film forming Active or Placebo to Molluscum.
Other Name: For use in applying VP-102 Drug or Placebo Vehicle




Primary Outcome Measures :
  1. Proportion of subjects exhibiting complete clearance of all treatable molluscum lesions (baseline and new) on the Day 84 visit (EOS). [ Time Frame: Treatment Visit Day 1 (Baseline) compared to Day 84 (EOS) visit. ]

Secondary Outcome Measures :
  1. Proportion of subjects exhibiting complete clearance of all treatable molluscum lesions (baseline and new) on the Day 63 visit. [ Time Frame: Treatment Visit Day 1 (Baseline) compared to Day 63 Treatment Visit. ]
  2. Proportion of subjects exhibiting complete clearance of all treatable molluscum lesions (baseline and new) on the Day 42 visit. [ Time Frame: Treatment Visit Day 1 (Baseline) compared to Day 42 Treatment Visit. ]
  3. Proportion of subjects exhibiting complete clearance of all treatable molluscum lesions (baseline and new) on the Day 21 visit. [ Time Frame: Treatment Visit Day 1 (Baseline) compared to Day 21 Treatment Visit. ]

Other Outcome Measures:
  1. Change from baseline of the composite score from the Children's Dermatology Life Quality Index (CDLQI) assessment at the EOS visit to measure the quality of life and impact of skin disease in the subset of subjects 4 -16 years of age. [ Time Frame: Measured at each Treatment Visit Day 1 (Baseline), 21, 42, 63 and Day 84 (EOS) visit. ]
  2. Percent reduction of all treatable molluscum lesions (baseline and new) from baseline at the EOS visit. [ Time Frame: Treatment Visit Day 1 (Baseline) compared to Day 84 (EOS) visit. ]
  3. Change from baseline in the number of treatable molluscum lesions (baseline and new) at the EOS visit. [ Time Frame: Treatment Visit Day 1 (Baseline) compared to Day 84 (EOS) visit. ]
  4. Proportion of subjects exhibiting a 75% or greater reduction of all treatable molluscum lesions (baseline and new) at the EOS visit. [ Time Frame: Treatment Visit Day 1 (Baseline) compared to Day 84(EOS) visit. ]
  5. Proportion of subjects exhibiting a 90% or greater reduction of all treatable molluscum lesions (baseline and new) at the EOS visit. [ Time Frame: Treatment Visit Day 1 (Baseline) compared to Day 84 (EOS) visit. ]
  6. Subject reported spread to household members as measured by any new occurrence of molluscum in household members of subject. [ Time Frame: Evaluated at Treatment Visit Days 1, 21, 42, 63 and 84(EOS). ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   2 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

To qualify for inclusion in this study, subjects must:

  1. Be healthy subjects, at least 2 years of age or older.
  2. Consent to having all molluscum lesions treated and the physician must be willing to treat all molluscum lesions initially present. Lesions within 10mm of the eyelid margins or the margin of any mucosal membrane should be evaluated carefully to ensure that they can be safely treated. Non-mucosal genital area lesions and inflamed lesions are considered treatable.
  3. Be otherwise medically healthy with no clinically significant medical history as determined by the investigator. Subjects exhibiting active Atopic Dermatitis may be enrolled.
  4. On day of treatment refrain from application of all topical agents including alcohol-based sanitary products and sunscreens for a minimum of 4 hours before Study drug application. Topical agents including alcohol-based sanitary products and sunscreens may be used after application of the study drug so long as they are not applied within 5cm of treated skin lesions.
  5. Refrain from swimming, bathing or prolonged immersion in water or any liquids until the Study drug is removed.
  6. Have the ability or have a guardian with the ability to follow study instructions and be likely to complete all study requirements.
  7. Provide written informed consent or assent in a manner approved by the institutional review board (IRB) and/or have a parent/guardian provide written informed consent as evidenced by the signature on an IRB approved assent/consent form.
  8. Provide written authorization for use and disclosure of protected health information.
  9. Agree to allow photographs to be taken, (selected sites only) of selected lesions at every visit that will be used for training, publication and future marketing brochures.

Exclusion Criteria:

Subjects will be excluded from the study if they:

  1. Are unable to cooperate with the requirements or visits of the study, as determined by the investigator.
  2. Are systemically immunosuppressed or are receiving treatments such as chemotherapy or other non-topical immunosuppressive agents.
  3. Have any lesions present at baseline in anatomic locations that the subject/parent/guardian or the physician is unwilling to treat.
  4. Have had any previous treatment of molluscum including the use of cantharidin, antivirals, retinoids, curettage or freezing of lesions in the past 14 days. Additional treatments should not be implemented during the course of the study.
  5. Have a history of illness or any dermatologic disorder which, in the opinion of the investigator, will interfere with accurate counting of lesions or increase the risk of adverse events.
  6. History or presence of clinically significant medical, psychiatric, or emotional condition or abnormality that, in the opinion of the investigator, would compromise the safety of the subject or the quality of the data.
  7. Have a history or presence of hypersensitivity or an idiosyncratic reaction to the Study drug or related compounds, or drug product excipients (acetone, ethyl alcohol, nitrocellulose, hydroxypropyl cellulose, castor oil, camphor, gentian violet, and denatonium benzoate).
  8. Have a condition or situation that may interfere significantly with the subject's participation in the study (e.g., subjects who required hospitalization in the 2 months prior to screening for an acute or chronic condition including alcohol or drug abuse), at the discretion of the investigator.
  9. Have received another investigational product within 14 days prior to the first application of the Study drug.
  10. Have been treated within 14 days with a product that contains cantharidin (topical or homeopathic preparations) for any reason prior to screening.
  11. Are sexually active or may become sexually active and are unwilling to practice responsible birth control methods. (e.g., combination of condoms and foam, birth control pills, intrauterine device, patch, shot and vaginal ring, etc.). Withdrawal is not an acceptable method of birth control. Females that have reached menarche must have a negative urine pregnancy test at each visit prior to treatment with Study drug.
  12. Are pregnant or breastfeeding.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03377790


Locations
United States, Alabama
Alabama Clinical Therapeutics
Birmingham, Alabama, United States, 35205
Southeastern Pediatric Associates
Dothan, Alabama, United States, 36305
United States, Arkansas
Applied Research Center of Arkansas
Little Rock, Arkansas, United States, 72212
United States, Florida
Study Protocol, Inc.,
Boynton Beach, Florida, United States, 33437
Skin Research Institute
Coral Gables, Florida, United States, 33146
ASCLEPES Research Center
Spring Hill, Florida, United States, 34609
Olympian Clinical Research
Tampa, Florida, United States, 33609
United States, Illinois
Summit Dermatology
Oakbrook Terrace, Illinois, United States, 60181
United States, Michigan
Clarkston Skin Research
Clarkston, Michigan, United States, 48346
United States, Missouri
St Louis Children's Hospital
Saint Louis, Missouri, United States, 63104
United States, Nebraska
Midwest Children's Hospital
Lincoln, Nebraska, United States, 68522
United States, New York
Kings County Hospital
Brooklyn, New York, United States, 11203
United States, North Carolina
University North Carolina Dermatology Center
Chapel Hill, North Carolina, United States, 27516
United States, Ohio
The Pediatric Associates of Fairfield, Inc
Fairfield, Ohio, United States, 45014
United States, Tennessee
Holston Medical Group
Bristol, Tennessee, United States, 37620
United States, Texas
Arlington Research Center
Arlington, Texas, United States, 66011
Center for Skin Research
Houston, Texas, United States, 77056
ACRC Trials Plano Pediatrics
Plano, Texas, United States, 75093
Sponsors and Collaborators
Verrica Pharmaceuticals Inc.
Instat Consulting, Inc.
Paidion Research, Inc.
Database Integrations, Inc.
Investigators
Principal Investigator: Lawrence Eichenfield, MD Rady Children's Hospital; San Diego, California

Responsible Party: Verrica Pharmaceuticals Inc.
ClinicalTrials.gov Identifier: NCT03377790     History of Changes
Other Study ID Numbers: VP-102-101
First Posted: December 19, 2017    Key Record Dates
Last Update Posted: September 14, 2018
Last Verified: December 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: Yes
Device Product Not Approved or Cleared by U.S. FDA: Yes
Pediatric Postmarket Surveillance of a Device Product: No

Keywords provided by Verrica Pharmaceuticals Inc.:
Molluscum
Skin Diseases
Poxviridae Infections
Skin Diseases; Infectious
Skin Diseases; Viral
DNA Poxvirus

Additional relevant MeSH terms:
Molluscum Contagiosum
Poxviridae Infections
DNA Virus Infections
Virus Diseases
Skin Diseases, Viral
Skin Diseases, Infectious
Skin Diseases
Pharmaceutical Solutions
Cantharidin
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action